ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD) succeeded in completing the enrollment process for its planned Phase IIa Alzheimer’s study ahead of schedule. It is a significant accomplishment for the company which will allow it to report the results of Anavex 2-73 well in defined period.
The planned Phase 2a study of Anavex 2-73 will evaluate the drug as an oral treatment for the fatal AD disease. With the enrollment completed ahead of schedule, Anavex expects to release trial data before the end of this year. The trial has enrolled as many as 32 individuals suffering from mild to moderate Alzheimer’s disease.
Providing the details on Anavex 2-73 Phase IIa study, Anavex stated that the primary endpoint is determination of MTD or maximum tolerated dose of investigational drug Anavex 2-73. The medication has already demonstrated potential in preclinical trials to prevent, halt, and overturn the course of the disease.
As noted before, the lead drug, in combination with standard care drug Donepezil, can potentially treat Alzheimer’s disease based on its mechanism of action. The Phase 2a study has multiple secondary endpoints, but presently the focus is to see the tolerability of the lead drug. It should be noted that the top line report from the Phase 2a trial can serve as a key catalyst.
Anavex stock had recorded substantial gains in July this year after the company confirmed encouraging initial Phase 2a data with drug ANAVEX 2-73 at the conference AAIC held in Washington DC. The report presented at the event provided early evidence of improving cognition condition in patients with Alzheimer’s. ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD) stock had recorded gains of over 1000% so far in this year, and in event of positive data from the Phase 2a report, the stock can further extend its gains for the year.